IMPAC

IMPACT Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted anti-cancer therapies, with a primary emphasis on DNA Damage Response (DDR) mechanisms and synthetic lethality. The company has established a comprehensive DDR pipeline, including PARP, Wee1, and ATR inhibitors, leveraging its proprietary drug discovery platform. Its lead candidate, senaparib (IMP4297), is a potent PARP inhibitor that has demonstrated promising results in late-stage clinical trials, including a successful Phase 3 trial for ovarian cancer maintenance. IMPACT Therapeutics aims to provide innovative treatment options for patients with advanced cancers through both monotherapy and combination strategies. Headquartered in Nanjing, China, with operations in the United States, the company collaborates with global partners like Junshi Biosciences to accelerate the delivery of its oncology portfolio.